Platelet Transfusion Indications in Patients with Hemorrhage

General Guidelines

• The American College of Critical Care Medicine and the American Society of Clinical Oncology recommend transfusing platelets to maintain a count ≥50,000/μL in patients with active hemorrhage and thrombocytopenia, regardless of the underlying mechanism of thrombocytopenia 1, 2
• The initial dose should be 4-8 units of individual platelets or one unit of apheresis, which contains 3-4 × 10¹¹ platelets and should increase the count by >30,000/μL 1, 2

Thresholds for Specific Types of Hemorrhage

• For active hemorrhage, the target platelet count is ≥50,000/μL 1, 2
• For central nervous system hemorrhage, the target platelet count is >100,000/μL in patients with traumatic brain injury and active hemorrhage, and >50,000/μL in non-traumatic intracranial hemorrhage 2
• For surgical procedures in the central nervous system, the conventional threshold is 80-100,000/μL 2

Considerations for Specific Mechanisms of Thrombocytopenia

• In patients with bone marrow failure (leukemia, chemotherapy, transplant), transfuse when there is active bleeding with a target ≥50,000/μL 1
• In patients with increased platelet destruction (dengue, immune thrombocytopenia), prophylactic transfusion is relatively contraindicated, and transfuse only if there is clinically significant bleeding with a target ≥50,000/μL 1, 3

Risk Factors that Modify the Decision

• Consider transfusion at higher thresholds (20,000-50,000/μL) in the presence of coagulopathy, anticoagulant use, advanced age, hypertension, peptic ulcer disease, recent trauma or surgery, or rapid decline in platelet count 1, 2, 4

Invasive Procedures in Patients with Hemorrhage

• For major procedures, the target platelet count is 40,000-50,000/μL 1
• For central venous catheter placement, the target platelet count is >20,000/μL 1
• For lumbar puncture, the target platelet count is >50,000/μL 1

P2Y12 Inhibitor Persistence, Assessment, and Transfusion Implications in Intracerebral Hemorrhage

Pharmacologic Persistence of P2Y12 Inhibitors

• Clopidogrel, prasugrel, and ticagrelor produce measurable inhibition of the P2Y12 receptor that can persist for several days after the last dose, which is relevant when evaluating low P2Y12 function in patients with intracerebral hemorrhage who deny antiplatelet use. Evidence level: pharmacologic studies demonstrating drug‑specific platelet inhibition kinetics. 5

Diagnostic Testing for P2Y12 Platelet Function

• The VASP (vasodilator‑stimulated phosphoprotein) assay is a validated laboratory test that specifically evaluates P2Y12 receptor activity and can be used to confirm true P2Y12 inhibition in the acute setting of intracerebral hemorrhage. Evidence level: validated assay methodology reported in peer‑reviewed research. 6

Transfusion Outcomes in Aspirin‑treated Intracerebral Hemorrhage

• In the PATCH randomized controlled trial, platelet transfusion administered to patients with aspirin‑associated intracerebral hemorrhage resulted in higher rates of mortality and dependence at three months compared with standard care, indicating that routine platelet transfusion may be harmful in this subgroup. Evidence level: high‑quality randomized trial. 7